|
Albini, A., and Sporn, M.B. (2007). The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7, 139-147. Ara, T., and Declerck, Y.A. (2010). Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46, 1223-1231. Balkwill, F. (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361-371. Barre, B., Vigneron, A., Perkins, N., Roninson, I.B., Gamelin, E., and Coqueret, O. (2007). The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 13, 4-11. Bhowmick, N.A., Neilson, E.G., and Moses, H.L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337. Bissell, M.J., and Radisky, D. (2001). Putting tumours in context. Nat Rev Cancer 1, 46-54. Blasberg, J.D., Pass, H.I., Goparaju, C.M., Flores, R.M., Lee, S., and Donington, J.S. (2010). Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28, 936-941. Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M.E., Neve, R.M., and Thompson, E.W. (2008). Epithelial mesenchymal 43 transition traits in human breast cancer cell lines. Clin Exp Metastasis 25, 629-642. Bonnomet, A., Brysse, A., Tachsidis, A., Waltham, M., Thompson, E.W., Polette, M., and Gilles, C. (2010). Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15, 261-273. Boye, K., and Maelandsmo, G.M. (2010). S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176, 528-535. Bremnes, R.M., Veve, R., Hirsch, F.R., and Franklin, W.A. (2002). The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36, 115-124. Chamberlain, G., Fox, J., Ashton, B., and Middleton, J. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25, 2739-2749. Chang, H.Y., Chi, J.T., Dudoit, S., Bondre, C., van de Rijn, M., Botstein, D., and Brown, P.O. (2002). Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99, 12877-12882. Cook, A.C., Tuck, A.B., McCarthy, S., Turner, J.G., Irby, R.B., Bloom, G.C., Yeatman, T.J., and Chambers, A.F. (2005). Osteopontin induces multiple changes in gene expression that reflect the six 44 "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 43, 225-236. De Wever, O., Pauwels, P., De Craene, B., Sabbah, M., Emami, S., Redeuilh, G., Gespach, C., Bracke, M., and Berx, G. (2008). Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130, 481-494. Fedarko, N.S., Jain, A., Karadag, A., Van Eman, M.R., and Fisher, L.W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7, 4060-4066. Grigorian, M., Ambartsumian, N., Lykkesfeldt, A.E., Bastholm, L., Elling, F., Georgiev, G., and Lukanidin, E. (1996). Effect of mts1 (S100A4) expression on the progression of human breast cancer cells. Int J Cancer 67, 831-841. Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12, 11-19. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 45 Hsu, Y.C., Fu, H.H., Jeng, Y.M., Lee, P.H., and Yang, S.D. (2006). Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 24, 3780-3788. Hu, Z., Lin, D., Yuan, J., Xiao, T., Zhang, H., Sun, W., Han, N., Ma, Y., Di, X., Gao, M., et al. (2005). Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11, 4646-4652. Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., and Mori, M. (2010). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101, 293-299. Joyce, J.A. (2005). Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513-520. Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252. Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W., Richardson, A.L., Polyak, K., Tubo, R., and Weinberg, R.A. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563. 46 Kim, Y.C., Wu, Q., Chen, J., Xuan, Z., Jung, Y.C., Zhang, M.Q., Rowley, J.D., and Wang, S.M. (2009). The transcriptome of human CD34+ hematopoietic stem-progenitor cells. Proc Natl Acad Sci U S A 106, 8278-8283. Knutson, K.L., Lu, H., Stone, B., Reiman, J.M., Behrens, M.D., Prosperi, C.M., Gad, E.A., Smorlesi, A., and Disis, M.L. (2006). Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177, 1526-1533. Kokkinos, M.I., Wafai, R., Wong, M.K., Newgreen, D.F., Thompson, E.W., and Waltham, M. (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs 185, 191-203. Le, Q.T., Chen, E., Salim, A., Cao, H., Kong, C.S., Whyte, R., Donington, J., Cannon, W., Wakelee, H., Tibshirani, R., et al. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12, 1507-1514. Lewis, C.E., and Pollard, J.W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66, 605-612. Liotta, L.A., and Kohn, E.C. (2001). The microenvironment of the tumour-host interface. Nature 411, 375-379. 47 Lopez-Novoa, J.M., and Nieto, M.A. (2009). Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1, 303-314. Lorusso, G., and Ruegg, C. (2008). The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130, 1091-1103. Mack, P.C., Redman, M.W., Chansky, K., Williamson, S.K., Farneth, N.C., Lara, P.N., Jr., Franklin, W.A., Le, Q.T., Crowley, J.J., and Gandara, D.R. (2008). Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26, 4771-4776. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 454, 436-444. Martin, F.T., Dwyer, R.M., Kelly, J., Khan, S., Murphy, J.M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F.P., et al. (2010). Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. Massberg, S., Schaerli, P., Knezevic-Maramica, I., Kollnberger, M., Tubo, N., Moseman, E.A., Huff, I.V., Junt, T., Wagers, A.J., Mazo, I.B., et al. (2007). Immunosurveillance by hematopoietic progenitor 48 cells trafficking through blood, lymph, and peripheral tissues. Cell 131, 994-1008. Nguyen, D.X., Bos, P.D., and Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274-284. Onder, T.T., Gupta, P.B., Mani, S.A., Yang, J., Lander, E.S., and Weinberg, R.A. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68, 3645-3654. Polyak, K., Haviv, I., and Campbell, I.G. (2009). Co-evolution of tumor cells and their microenvironment. Trends Genet 25, 30-38. Qian, B.Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51. Rangaswami, H., Bulbule, A., and Kundu, G.C. (2006). Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16, 79-87. Rudland, P.S., Platt-Higgins, A., Renshaw, C., West, C.R., Winstanley, J.H., Robertson, L., and Barraclough, R. (2000). Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 60, 1595-1603. Sheehan, K.M., Gulmann, C., Eichler, G.S., Weinstein, J.N., Barrett, H.L., Kay, E.W., Conroy, R.M., Liotta, L.A., and Petricoin, E.F., 3rd (2008). Signal pathway profiling of epithelial and stromal 49 compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 27, 323-331. Spaeth, E.L., Dembinski, J.L., Sasser, A.K., Watson, K., Klopp, A., Hall, B., Andreeff, M., and Marini, F. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4, e4992. Sullivan, N.J., Sasser, A.K., Axel, A.E., Vesuna, F., Raman, V., Ramirez, N., Oberyszyn, T.M., and Hall, B.M. (2009). Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940-2947. Suzuki, M. (1989). SPXX, a frequent sequence motif in gene regulatory proteins. J Mol Biol 207, 61-84. Thiery, J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454. Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890. Thiery, J.P., and Sleeman, J.P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142. 50 Thomas, P.A., Kirschmann, D.A., Cerhan, J.R., Folberg, R., Seftor, E.A., Sellers, T.A., and Hendrix, M.J. (1999). Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 5, 2698-2703. Tse, J.C., and Kalluri, R. (2007). Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101, 816-829. Vandenheede, J.R., Yang, S.D., Goris, J., and Merlevede, W. (1980). ATP x Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. J Biol Chem 255, 11768-11774. Wai, P.Y., and Kuo, P.C. (2004). The role of Osteopontin in tumor metastasis. J Surg Res 121, 228-241. Wai, P.Y., and Kuo, P.C. (2008). Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27, 103-118. Witz, I.P. (2008). Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res 68, 9-13. Woodgett, J.R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9, 2431-2438. 51 Wu, Y., and Zhou, B.P. (2010). TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102, 639-644. Xue, C., Plieth, D., Venkov, C., Xu, C., and Neilson, E.G. (2003). The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63, 3386-3394. Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14, 818-829. Yang, S.D. (1986). Identification of the ATP.Mg-dependent protein phosphatase activator (FA) as a myelin basic protein kinase in the brain. J Biol Chem 261, 11786-11791. Yang, S.D. (2004). Proline-directed protein kinase FA as a potential target for diagnosis and therapy of human cancers. Curr Cancer Drug Targets 4, 591-596. Yang, S.D., Vandenheede, J.R., Goris, J., and Merlevede, W. (1980). ATP x Mg-dependent protein phosphatase from rabbit skeletal muscle. I. Purification of the enzyme and its regulation by the interaction with an activating protein factor. J Biol Chem 255, 11759-11767. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51.
|